Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.230
-0.050 (-1.52%)
At close: Sep 3, 2026, 4:00 PM EDT
3.240
+0.010 (0.31%)
After-hours: Sep 3, 2026, 7:30 PM EDT

Altimmune Revenue

Altimmune had revenue of $31.00K in the twelve months ending June 30, 2026, up 55.00% year-over-year. In the year 2025, Altimmune had annual revenue of $41.00K with 105.00% growth.

Revenue (ttm)
$31.00K
Revenue Growth
+55.00%
P/S Ratio
20,267.49
Revenue / Employee
$544
Employees
57
Market Cap
628.29M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202541.00K21.00K105.00%
Dec 31, 202420.00K-406.00K-95.31%
Dec 31, 2023426.00K494.00K-
Dec 31, 2022-68.00K-4.48M-
Dec 31, 20214.41M-3.78M-46.12%
Dec 31, 20208.19M2.38M41.09%
Dec 31, 20195.80M-4.53M-43.85%
Dec 31, 201810.33M-407.15K-3.79%
Dec 31, 201710.74M7.50M231.82%
Dec 31, 20163.24M-7.40M-69.59%
Dec 31, 201510.64M450.46K4.42%
Dec 31, 201410.19M-7.72M-43.11%
Dec 31, 201317.91M-7.26M-28.85%
Dec 31, 201225.18M909.61K3.75%
Dec 31, 201124.27M3.27M15.59%
Dec 31, 201020.99M-6.56M-23.80%
Dec 31, 200927.55M-5.36M-16.29%
Dec 31, 200832.91M18.27M124.75%
Dec 31, 200714.64M12.98M780.39%
Dec 31, 20061.66M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Arvinas316.70M
REGENXBIO174.48M
Valneva SE163.30M
Autolus Therapeutics117.39M
ARS Pharmaceuticals116.93M
Capricor Therapeutics11.13M
Prime Medicine4.07M
Revenue Rankings